flow study semaglutide 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants FLOW Trial: Semaglutide Lowers Risk

doi: 10.1016/j.jconrel.2024.01.030

Recent experimental and a few clinical research findings have found sufficient physiopathological evidence that proves that an excess of energy reserves in humans with problems such as nonalcoholic fatty liver disease or diabetes is harmful

Benefits and Effectiveness in Managing Type 2 Diabetes Clinical trials have consistently demonstrated that GLP-1 receptor agonists are highly effective at improving glycaemic control in type 2 diabetes

Metabolic and Endocrine Effects Semaglutide affects multiple metabolic parameters

(7) Thats a lengthy list of supplements

slim, but having very little muscle mass/tone